TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Solasia Pharma KK ( (JP:4597) ) just unveiled an update.
Solasia Pharma has announced a reduction in its capital stock and legal capital surplus, aiming to improve its financial flexibility and enable shareholder returns. These changes are part of an internal accounting adjustment and will not impact the total shares issued or owned by shareholders, but are designed to allow the company to better manage its capital policy and address a retained loss of 3,633 million yen as reported at the end of 2024.
More about Solasia Pharma KK
Solasia Pharma K.K. is a specialty pharmaceutical company focusing on the development and commercialization of oncology products. The company also operates as a biotechnology venture, requiring significant upfront investment for its clinical trials and research, which are necessary for long-term revenue generation.
YTD Price Performance: 9.47%
Average Trading Volume: 304
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: €51.4M
See more data about 4597 stock on TipRanks’ Stock Analysis page.